41 results about "Inflammatory genes" patented technology

Neurotrophin binding to its specific receptors Trk A and p75 leads to the activation of multiple signalling cascades, culminating in neuroprotective and regenerative effects, including neuronal survival and neurite outgrowth. Neurotrophic factors have been used for the treatment of several neurodegenerative diseases. However, their use is limited by their inability to cross the blood-brain barrier, their short half life and their side effects. Small molecule neurotrophin mimetics may be beneficial in treating a number of neurodegenerative disorders. The present invention shows the capacity of nerve growth factor agonist molecules of Formulae I-IV, as defined in the specification, to induce differentiation in PC 12 cells, promote survival in RN22 cells and activate Trk A, IkBa and SAPK/JNK phosphorylation to various extents in both cell lines. In addition these molecules were able to ameliorate acute experimental autoimmune encephalomyelitis (EAE), a multiple sclerosis (MS) animal model, inhibiting brain inflammation and reducing brain damage. We also observed suppression in the production of pro-inflammatory genes like the inducible nitric oxide synthase. These small molecules with NGF agonist activity may be beneficial for MS and other neurodegenerative diseases due to its neuroprotective and immunomodulatory properties.

The present invention relates to a novel use of a thiourea derivative and, more specifically, to a pharmaceutical composition for preventing or treating autoimmune diseases comprising a thiourea derivative as an active ingredient. The thiourea derivative according to the present invention can inhibit the transcription of inflammatory genes such as TNF-α, IL-1β, NOS2 and IL-6, and also can inhibit the activity or production of Th17 and increase the activity or production of a regulatory T cell (Treg). Thus, it is expected that the thiourea derivative may be usefully used in a pharmaceutical composition, a health food composition, etc. for the prevention, improvement or treatment of various autoimmune diseases including rheumatoid arthritis.

The invention discloses an application of 5-pentyl-3-methoxy-phenol to preparation of products for preventing and treating oxidative stress or inflammatory response induced diseases. The chemical formula of 5-pentyl-3-methoxy-phenol is shown in the description. 5-pentyl-3-methoxy-phenol is an Nrf2 (nuclear factor-erythroid 2-related factor 2) signaling pathway agonist and an NF (nuclear factor)-kappa B signaling pathway inhibitor. 5-pentyl-3-methoxy-phenol can up-regulate the protein levels of Nrf2 as well as phase II detoxification enzyme NQO1 and antioxidant enzyme GCLM which are regulated by Nrf2, increase the level of glutathione as an endogenous antioxidant and inhibit generation of exogenous toxicant induced reactive oxygen species, and has a protective effect on exogenous toxicant induced oxidative damage to pulmonary bronchial epithelial cells, glomerular mesangial cells, human nerve cells and human breast cancer cells. 5-pentyl-3-methoxy-phenol can inhibit activation of an NF-kappa B signaling pathway, down-regulate inflammatory gene expression and inhibit LPS induced inflammatory response of macrophage RAW 264.7 of a mouse.

The invention described herein relates to methods of screening for pro-inflammatory genes and anti-inflammatory genes which may be useful for treating an inflammatory disease, disorder, or otherwise abnormal condition, such as an inflammatory lung disease. The identified pro-inflammatory genes and anti-inflammatory genes may be used to produce pharmaceutical compositions for use in treating the inflammatory disease, disorder, or otherwise abnormal condition.

The invention discloses an experimental method for treating mastitis by using pedunculoside. The experimental method specifically comprises the following steps: S1, selecting ICR mice 3-7 days after childbirth as experimental objects in the experiment; and dividing the ICR mice into five groups, namely a blank control group (NT), an administration group (PE), a mastitis model group (LPS), a drug therapy group (LPS+PE) and a dexamethasone positive control group (LPS+DEX), wherein each group comprises 9 mice; and S2, anesthetizing and fixing the mice by using pentobarbital sodium (45mg/kg), injecting LPS (0.2 mg/kg) into a fourth pair of nipples of the mice to construct a mastitis model, and collecting a sample after 24 hours. The invention discloses an experimental method for treating mastitis by using pedunculoside. Pathological damage conditions of mammary gland tissues are detected by a paraffin section method, expression conditions of inflammatory genes IL-1[beta] in the mammary gland tissues are evaluated by a fluorescent quantitative PCR technology, and experimental results show that pedunculoside can effectively treat LPS-induced mastitis.

The invention discloses novel application of dictamnine, in particular to application of the dictamnine in preparing type I hypersensitivity reaction drugs caused by mast cell activation, and belongsto the field of pharmaceuticals. According to the dictamnine disclosed by the invention, by constructing a C48/80 induced P815 mast cell in vitro inflammatory model, the dictamnine is found to have the effects of inhibiting the activation of mast cells, effectively inhibiting the degranulation degree of the mast cells in a sensitized state and alleviating the release of beta-hexosaminidase; the expression of inflammatory genes IL-4, IL-6, IL-12 and IL-13 in the mRNA level can be inhibited; in addition, the phosphorylation level of ERK in an intracellular signaling pathway can be significantlyinhibited.

The sesquiterpene lactone extract from Artemisia leucodes is a potent anti-inflammatory agent in vivo. Methods of obtaining the anti-inflammatory extract and methods of treating inflammation with the extract are disclosed. A product comprising the Artemisia leucodes total sesquiterpene lactone extract is useful for treatment of inflammation.

The invention provides application of a CD146 + mesenchymal stem cell subset in preparation of a medicine for preventing and treating premature ovarian failure, and belongs to the technical field of biological medicines. The invention provides an application of a CD146 + mesenchymal stem cell subset in preparation of a medicine for preventing and treating premature ovarian failure. The treatment efficiency of the CD146 + MSCs and the treatment efficiency of the CD146-MSCs on a mouse POF model are compared, compared with a model group, the MSCs remarkably improve the premature ovarian failure, and the CD146 + subgroup has a slightly good trend compared with the CD146-MSCs. Meanwhile, the invention also provides an application of the CD146 + mesenchymal stem cell subset in preparation of a medicine for improving the immunoregulation ability of a premature ovarian failure patient. Experiments show that the CD146 + mesenchymal stem cell subgroup can significantly reduce the expression level of chemotactic factors and inflammatory genes and inhibit T cell proliferation, which indicates that the CD146 + subgroup has better immunoregulation ability.

The invention relates to the field of cell biology, in particular to an exosome containing CD10-dm protein and capable of targeting brain tissues as well as a preparation method and application of the exosome. The exosome is loaded with CD10 protein with enhanced enzymatic activity and specificity, and RVG oligopeptide which can be combined with a brain nerve cell acetylcholine receptor in a targeted manner is shown on the surface of the exosome. After intravenous administration, the exosome can penetrate through a blood brain barrier and is specifically combined with positive nerve cells of an acetylcholine receptor, so that the CD10-dm protein is delivered into the nerve cells, A beta protein causing the Alzheimer's disease is efficiently and specifically degraded, the expression of anti-inflammatory genes is enhanced, and the expression of pro-inflammatory genes is inhibited. In addition, the exosome is compatible with recipient cells, does not cause immune response and inflammatory response of receptors, can significantly reduce toxic and side effects of gene therapy, and has a positive effect on treatment of the Alzheimer's disease.

The invention belongs to the technical field of medicine and particularly relates to a separation and preparation method of dihydrosanguinarine and application thereof in the preparation of anti-inflammatory drugs. The dihydrosanguinarine (to LC-PDA analytical purity, under structural identification via MS, 1H-NMR and 13C-NMR) is attained by performing condensing reflux extraction on bunge corydalis herb, concentrating, extracting with an organic solvent, and performing column chromatography separation. The dihydrosanguinarine can evidently inhibit transcription of LPS-induced RAW 264.7 cell inflammatory gene iNOS, TNF-alpha, IL-1 beta and IL-6, thereby inhibiting the release of inflammatory medium NO and the expression level of TNF-alpha, IL-1 beta and IL-6 proteins. The research on anti-inflammatory effect mechanism shows that the dihydrosanguinarine can inhibit the expression level of TLR4 and TLR2 in LPS-induced RAW 264.7 cell inflammatory signal pathways and the phosphorylation ofI kappa B alpha and p65 in NF-kappa B, namely the dihydrosanguinarine can resist inflammation by inhibiting the activation of TLRs/NF-kappa B inflammation signal pathway.

The invention provides application of lactobacillus rhamnosus in relieving intestinal inflammation, and belongs to the field of probiotic functions. In order to solve the problem that the existing medicines for relieving intestinal inflammation have relatively serious side effects, the invention provides the lactobacillus rhamnosus JL1 which has the function of relieving intestinal inflammation, and the lactobacillus rhamnosus JL1 has the function of relieving intestinal inflammation. Reduction of intestinal inflammation is verified by inhibiting expression of pro-inflammatory genes TNF-alpha, IL-1beta and IL-6 in LPS-induced Caco-2 cells, a clinical state of a mouse and ileum dissection observation.

The invention, which belongs to the technical field of external psoriasis treatment materials, particularly relates to a hydrogel medical dressing for treating psoriasis, wherein the hydrogel medicaldressing is alginate/polyacrylamide interpenetrating network structure hydrogel chemically crosslinked with rubidium, magnesium and zinc ions. In addition, the invention also provides a preparation method of the dressing and application of the dressing in preparation of a psoriasis treatment preparation. According to the interpenetrating network hydrogel, rubidium, magnesium and zinc ions are innovatively and chemically crosslinked in the alginate/polyacrylamide interpenetrating network structure hydrogel; because of the interaction of the interpenetrating network polymer and rubidium, magnesium and zinc ions cross-linked with the interpenetrating network polymer, no obvious toxicity to cuticle cell proliferation is caused, the cuticle cell inflammatory gene expression is reduced, and thetreatment of psoriasis is realized.

The disclosure provides a method for treating a subject afflicted with a tumor comprising administering to the subject a therapeutically effective amount of an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or antigen-binding portion thereof, wherein the subject is identified as having a high inflammatory gene signature score. In some embodiments, the high inflammatory gene signature score is determined by measuring the expression of a panel of inflammatory genes in a tumor sample obtained from the subject, wherein the inflammatory gene panel comprises CD274 (PD-L1), CD8A, LAG3, and STAT1.

Use of an AR antagonist, e.g., enzalutamide and other known AR antagonists, for reducing inflammatory genes of COVID-19 subjects is provided by the present invention. In other aspects, the present invention is directed to the use of an AR antagonist, e.g., the drug enzalutamide and other known AR antagonists, to treat lung cancer in a subject. In yet other aspects, the present invention is directed to an AR antagonist, e.g., the drug enzalutamide and other known AR antagonists, as an immunotherapy.

The invention discloses the use of an L-Plastin gene, which is an application of the L-Plastin gene as a drug target in screening a type I hypersensitivity targeted therapeutic inhibitor, and the invention is induced by constructing a sensitizer C48/80 The P815 mast cell in vitro allergy model found that L-Plastin knockdown has the effect of inhibiting mast cell activation, can effectively inhibitthe degree of degranulation of mast cells in sensitized state, and relieve the release of histamine and beta-hexosaminidase Represses the synthesis and secretion of inflammatory factors; inhibits theexpression of inflammatory genes and the expression of key receptors in the mast cell activation pathway, and significantly inhibits the RAF-MEK-ERK signaling pathway and inhibits AKT in the intracellular signaling pathway. Phosphorylation levels have been shown to have anti-allergic effects at the cellular level, providing a theoretical basis for clinical treatment of type I hypersensitivity reactions and the application of screening for new drug targets.

The invention provides application of HIPK2 in sepsis prediction and diagnosis, belongs to the technical field of biomedicine and disease diagnosis, and provides application of HIPK2 in preparation of a sepsis risk prediction, diagnosis and disease course monitoring reagent. The invention discloses an application of HIPK2 in preparation of a septicemia prediction and diagnosis reagent, and verifies that the transcriptional level of HIPK2 in peripheral blood mononuclear cells of a septicemia patient is significantly reduced, and HIPK2 is negatively correlated with a pro-inflammatory gene IL1B and positively correlated with an anti-inflammatory gene IL10; the cellular level experiments find that HIPK2 can inhibit generation of pro-inflammatory cytokines; therefore, the probability that healthy people with low expression of the HIPK2 develop into septicemia during microbial infection can be increased, so that the HIPK2 can be used as a potential septicemia prediction and diagnosis biomarker. According to the invention, a theoretical basis and a new detection method are provided for septicemia prediction and diagnosis.